Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest announcement is out from Nurix Therapeutics ( (NRIX) ).
Nurix Therapeutics unveiled promising data from its Phase 1a/1b trial of NX-5948 at the ASH Annual Meeting, showcasing a strong objective response rate of 75.5%, increasing to 84.2% with extended treatment. This BTK degrader showed a favorable safety profile and efficacy in patients with challenging genetic mutations, including those resistant to prior therapies. The trial continues to enroll participants, with pivotal trials set for 2025, marking a significant stride in tackling relapsed or refractory CLL/SLL.
See more insights into NRIX stock on TipRanks’ Stock Analysis page.
